Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

rare disease unit

This page shows the latest rare disease unit news and features for those working in and with pharma, biotech and healthcare.

Sanofi gets EU OK for Ablynx flagship drug Cablivi

Sanofi gets EU OK for Ablynx flagship drug Cablivi

The new drug is the first new product to come from Sanofi’s push into rare disease therapies and specifically rare blood disorders, which was also behind its $11.6bn acquisition ... s Genzyme rare disease unit.

Latest news

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    Pfizer Rare Disease Research Unit. ... Novartis and Morphosys gave up on their bimagrumab for muscle-wasting disease sporadic inclusion body myositis two years ago, while Shire/Acceleron and Amgen have also chalked up failures in this

  • Dupixent bounce-back helps stem diabetes declines at Sanofi Dupixent bounce-back helps stem diabetes declines at Sanofi

    Rare disease unit Genzyme had a good quarter, with sales up 6% to 743m, but vaccines business Sanofi Pasteur was under pressure with sales falling almost 16% to 811m due to ... hoping that the 3.9bn takeover of antibody specialist Ablynx and lead rare

  • Pfizer’s flat sales focus investor attention on M&A Pfizer’s flat sales focus investor attention on M&A

    Vaccines for Clostridium difficile and staphylococcal infections and a new-generation Prevnar are making progress, along with rare disease therapies tafamidis for neuropathies and rivipansel for vaso-occlusive crises and tanezumab ... In the last few

  • Sanofi warns of difficult few months as diabetes sales slump Sanofi warns of difficult few months as diabetes sales slump

    The loss of patent protection for kidney disease drug Renvela/Renagel (sevelamer) also took its toll, according to chief executive Olivier Brandicourt, the architect of the turnaround plan at Sanofi, who ... Revenues were however fairly flat if exchange

  • P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

    P&G agrees $4.2bn buy of Merck KGaA’ s consumer health unit. ... In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest from PMHub

  • Focus on Rare Diseases

    Lucid’ s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU. ... For further information about working with Lucid’ s Rare Disease Business Unit, please call Alison on 01494

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Quick links

Infographics

Multimedia